Summit Therapeutics (SMMT) Change in Receivables (2019 - 2023)

Summit Therapeutics has reported Change in Receivables for 5 years, with the latest figure at -$3000.0 in Q3 2023.

• For the quarter ending Q3 2023, Change in Receivables rose 99.76% year-over-year to -$3000.0; the trailing twelve-month figure through Jun 2024 stood at -$3000.0 (up 98.25% YoY), and the FY2023 full-year result was -$359000.0, up 63.18% from the prior year.
• Change in Receivables for Q3 2023 stood at -$3000.0, up from -$6000.0 in the prior quarter.
• The five-year high for Change in Receivables was $3.5 million in Q3 2020, with the low at -$3.7 million in Q4 2020.
• Historically, Change in Receivables has averaged -$193562.5 across 5 years, with a median of -$178000.0 in 2023.
• The largest YoY upside for Change in Receivables was 251.5% in 2022 against a maximum downside of 499.12% in 2022.
• Summit Therapeutics' Change in Receivables stood at -$2.7 million in 2019, then slumped by 37.3% to -$3.7 million in 2020, then surged by 74.76% to -$932000.0 in 2021, then jumped by 251.5% to $1.4 million in 2022, then tumbled by 100.21% to -$3000.0 in 2023.
• The last three Change in Receivables figures came in at -$3000.0 (Q3 2023), -$6000.0 (Q2 2023), and -$350000.0 (Q1 2023), per Business Quant data.